Cargando…
SMYD3 contributes to a more aggressive phenotype of prostate cancer and targets Cyclin D2 through H4K20me3
Prostate cancer (PCa) is one of the most incident cancers worldwide but clinical and pathological parameters have limited ability to discriminate between clinically significant and indolent PCa. Altered expression of histone methyltransferases and histone methylation patterns are involved in prostat...
Autores principales: | Vieira, Filipa Quintela, Costa-Pinheiro, Pedro, Almeida-Rios, Diogo, Graça, Inês, Monteiro-Reis, Sara, Simões-Sousa, Susana, Carneiro, Isa, Sousa, Elsa Joana, Godinho, Maria Inês, Baltazar, Fátima, Henrique, Rui, Jerónimo, Carmen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4537039/ https://www.ncbi.nlm.nih.gov/pubmed/25980436 |
Ejemplares similares
-
SMYD3 Promotes Cell Cycle Progression by Inducing Cyclin D3 Transcription and Stabilizing the Cyclin D1 Protein in Medulloblastoma
por: Asuthkar, Swapna, et al.
Publicado: (2022) -
Anti-neoplastic properties of hydralazine in prostate cancer
por: Graça, Inês, et al.
Publicado: (2014) -
Upregulation of SMYD3 and SMYD3 VNTR 3/3 polymorphism increase the risk of hepatocellular carcinoma
por: Binh, Mai Thanh, et al.
Publicado: (2020) -
The SMYD3-MAP3K2 signaling axis promotes tumor aggressiveness and metastasis in prostate cancer
por: Ikram, Sabeen, et al.
Publicado: (2023) -
MicroRNA-27a-5p regulation by promoter methylation and MYC signaling in prostate carcinogenesis
por: Barros-Silva, Daniela, et al.
Publicado: (2018)